Two years after IPO, Theseus Pharmaceuticals lays off most its staff, explores sale


Another biotech that went public in the IPO rush of 2021 is on the verge of a shutdown.

Previous 'The sooner we can move forward ... the better': Council consensus on Atlanta Medical Center site starts to fray
Next ProKidney names new CEO, pauses manufacturing but says it has enough cash to get to Q4 2025